Navigation Links
iCardiac Expands Sales and Marketing Team

Adds Industry Veteran with Over Two Decades of Cardiovascular Core Lab Experience

Rochester, NY (PRWEB) August 6, 2009 -- iCardiac Technologies, Inc., a leader in advanced cardiac safety ECG services and automated QT analysis, announced that it has expanded its sales and marketing team by hiring Susan Boyle as Senior Director of Business Development. Ms. Boyle has over two decades of experience in operations and business development in the clinical research industry, specializing in centralized cardiovascular diagnostic services at a number of leading core laboratories.

"We are excited to welcome Susan to the iCardiac team," said Sasha Latypova, Executive Vice President. "Susan's deep client relationships and long history of successfully partnering with clinical pharmacology units will allow iCardiac to better serve its rapidly broadening set of customers and channel relationships."

"I am proud to join iCardiac at this exciting transformation point in the cardiac core laboratory industry," said Ms. Boyle. "iCardiac has driven a dramatic shift in the industry by establishing the company as both a leader in Highly Automated QT evaluation as well as advanced techniques for avoiding false positives and negatives in cardiac safety studies."

About iCardiac Technologies
iCardiac Technologies, Inc. is a technologically differentiated cardiac core lab providing expert scientific consultation, end-to-end project management, statistical analysis and the industry's most sophisticated FDA-accepted cardiac safety assessment methodologies. iCardiac's analysis service provides drug developers with more precise and cost-effective methods for ECG/QT interval measurements, including Highly Automated QT, which has been validated by pharmaceutical companies and is now used in regulatory submissions as equivalent to the manual evaluation of ECGs in Thorough QT studies. In addition, iCardiac provides Beyond QT, a suite of advanced ECG-based cardiac safety markers that have been accepted and used as secondary end-points by the regulators, and deliver a more accurate assessment of the cardiac safety profile of drugs in development. iCardiac's COMPAS technology has been used for over a decade in cardiac clinical trials conducted for and by leading large and medium sized pharmaceutical, biotechnology, and medical device companies. For more information, visit:

# # #

Read the full story at

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. iCardiac Reports Significant Revenue Growth and Profitability
2. iCardiac Applies Advanced Cardiac Safety Biomarkers in Clinical Study for Top Pharmaceutical Company
3. iCardiac Selected for Multiple Cardiac Safety Studies
4. iCardiac Selected by Top 10 Pharmaceutical Company
5. iCardiac Processes Volume of Data Equivalent to One Thousand Traditional Thorough QT Studies
6. ATS Medical Expands Open Pivot Heart Valve Offerings
7. SAFC Expands Hi-Potency API Manufacturing and Introduces Solid-Form Testing at Its Madison Facility
8. BioLife Solutions Expands Scientific Advisory Board
9. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
10. SAFC Expands European Commercial Manufacturing and Storage Capacities With $10 Million Investment
11. Pharsight Expands Strategic Consulting Services Team
Post Your Comments:
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... Houston Methodist Willowbrook Hospital has signed ... to serve as their official health care provider. ... will provide sponsorship support, athletic training services, and ... volunteers, athletes and families. "We are ... and to bring Houston Methodist quality services and ...
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
Breaking Biology Technology:
(Date:6/9/2016)... control systems is proud to announce the introduction of fingerprint attendance control software, allowing ... are actually signing in, and to even control the opening of doors. ... ... ... Photo - ...
(Date:6/2/2016)... YORK , June 2, 2016   The Weather ... is announcing Watson Ads, an industry-first capability in which consumers ... by being able to ask questions via voice or text ... Marketers have long sought ... the consumer, that can be personal, relevant and valuable; and ...
(Date:5/16/2016)... YORK , May 16, 2016   EyeLock ... solutions, today announced the opening of an IoT Center ... to strengthen and expand the development of embedded iris ... an unprecedented level of convenience and security with unmatched ... authenticate one,s identity aside from DNA. EyeLock,s platform uses ...
Breaking Biology News(10 mins):